Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody class drugs
2 results
Beyfortus (nirsevimab)
(nirsevimab)Sanofi Pasteur Inc.
Usage: BEYFORTUS is indicated for preventing Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season and in children up to 24 months at risk of severe RSV disease through their second RSV season.
Synagis (palivizumab)
(palivizumab)Swedish Orphan Biovitrum AB (publ)
Usage: Synagis is indicated for preventing serious lower respiratory tract disease caused by RSV in pediatric patients with a history of premature birth, bronchopulmonary dysplasia requiring treatment, or hemodynamically significant congenital heart disease, all under specific age limits at the start of RSV season.